Triptorelin
Also known as: Decapeptyl, GnRH agonist
Triptorelin is a long-acting gonadotropin-releasing hormone agonist and a TGA-approved prescription medicine used for certain hormone-sensitive conditions. It is a prescription-only medicine.
- Category
- Reproductive / Hormonal
- Reported half-life
- Reported to vary by formulation; long-acting depot forms extend activity over weeks to months
- Common forms
- Prescription depot injection, Long-acting clinical formulations
- Research status
- TGA-approved prescription medicine (for example, in certain hormone-sensitive conditions). Use is prescription-only and clinically supervised.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to suppress sex hormone production after initial stimulation
- Used clinically for certain hormone-sensitive conditions
- Studied in several reproductive and oncology-related contexts
How it is reported to work
Triptorelin is described as a synthetic GnRH agonist that initially stimulates the pituitary but, with sustained exposure, downregulates GnRH receptors and reduces luteinising hormone, follicle-stimulating hormone and downstream sex hormones. This reported suppression underlies its approved clinical uses. These descriptions come from clinical literature for a regulated prescription medicine.
Background
Triptorelin is a long-acting GnRH agonist and a TGA-approved prescription medicine used for certain hormone-sensitive conditions. It is prescription-only and clinically supervised. This page is educational information, not medical advice, and does not recommend use.
What the research shows
Clinical literature reports that triptorelin first stimulates and then suppresses sex hormone production, which underlies its approved uses. These are reported clinical findings within a regulated medicine.
| Feature | Reported status |
|---|---|
| Class | GnRH agonist |
| Net effect (sustained) | Hormone suppression |
| Access | Prescription-only (TGA-approved) |
What people use it for (reported)
Triptorelin’s uses are clinical and prescriber-directed, and its effects depend on careful selection of formulation and monitoring. Online discussion is not a substitute for medical guidance, and anecdotes are not validated outcomes or established facts. Because sustained GnRH agonism profoundly changes sex hormone levels, any use outside a supervised clinical setting carries significant and poorly characterised risk.
Things to be aware of
As a prescription-only, TGA-approved medicine, triptorelin is meant to be used under professional supervision and carries recognised hormonal side effects. Self-sourced product purity cannot be verified.
If you have a relevant condition, the appropriate step is to consult a qualified healthcare professional. This article does not endorse self-sourcing or self-administering triptorelin.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to suppress sex hormone production after an initial stimulation phase, underlying its approved clinical uses
- Used clinically in certain hormone-sensitive conditions such as prostate cancer and endometriosis
- Long-acting depot formulations are reported to allow infrequent, supervised dosing
- Studied for use in central precocious puberty and assisted reproduction
Common side effects
- Hot flushes and sweating related to lowered sex hormones
- Reduced libido and sexual dysfunction
- Injection-site reactions
- Fatigue or low energy
- Headache and mood changes
Rare / serious side effects
- Initial symptom flare from the early hormone surge, which can transiently worsen the underlying condition
- Reduced bone mineral density with prolonged suppression
- Rare pituitary apoplexy reports following administration
- Allergic or hypersensitivity reactions
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of Triptorelin. Listed so you can make an informed decision, not to suggest any use is safe.
- Off-label use to suppress hormones for non-medical reasons without monitoring of bone density or metabolic effects
- Self-administration of grey-market depot product of unverified purity and dose
- Use without managing the initial testosterone or oestrogen flare, which can be harmful in hormone-sensitive disease
- Prolonged unsupervised suppression risking lasting effects on fertility, bone and cardiovascular health
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported to cause an early hormone surge within hours to days, followed by sustained suppression of sex hormones developing over the following weeks.
First effects
initial hormone surge reported within hours to first days
Noticeable change
transition from stimulation to suppression with falling sex hormones over weeks
Clear results
sustained hormone suppression and clinical response assessed over weeks to months
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take Triptorelin. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Intramuscular or subcutaneous depot injection (clinician-administered, prescriber-directed) |
|---|---|
| Typical reported dose | Approved depot formulations are reported at approximately 3.75 mg every 4 weeks, or 11.25 mg every 12 weeks, depending on the product and indication |
| Frequency | Every 4 weeks (3.75 mg) or every 12 weeks (11.25 mg), as prescribed |
| Cycle length | Duration is set by the prescriber according to the clinical indication and may extend over months |
Reported reconstitution (mg → units)
Depot formulations are pre-formulated and prepared by the administering clinic; they are not reconstituted by the recipient
Work out the units for your vial → CalculatorReported clinical use is prescriber-directed: depot injections are typically given at fixed intervals (for example monthly or three-monthly long-acting forms) under specialist supervision for the approved indication. This is reported information about a TGA-approved prescription medicine, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Both act on GnRH receptors and are discussed together when contrasting stimulation versus suppression
Discussed together in reproductive-axis research
Hormone-sensitive condition therapies
Reported clinically alongside other agents managing prostate or gynaecological conditions
Safety notes
Triptorelin is a prescription-only medicine intended for use under qualified medical supervision, with recognised hormonal side effects. Suppressing sex hormones has significant systemic effects. Anyone with a relevant condition should consult a qualified healthcare professional rather than self-experimenting.